323 related articles for article (PubMed ID: 19755606)
1. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions.
Shammas A; Lim R; Charron M
Radiographics; 2009; 29(5):1467-86. PubMed ID: 19755606
[TBL] [Abstract][Full Text] [Related]
2. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography/computed tomography potential pitfalls and artifacts.
Wang X; Koch S
Curr Probl Diagn Radiol; 2009; 38(4):156-69. PubMed ID: 19464586
[TBL] [Abstract][Full Text] [Related]
4. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.
Israel O; Yefremov N; Bar-Shalom R; Kagana O; Frenkel A; Keidar Z; Fischer D
J Nucl Med; 2005 May; 46(5):758-62. PubMed ID: 15872347
[TBL] [Abstract][Full Text] [Related]
5. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
6. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
[TBL] [Abstract][Full Text] [Related]
7. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
Jerushalmi J; Frenkel A; Bar-Shalom R; Khoury J; Israel O
J Nucl Med; 2009 Jun; 50(6):849-53. PubMed ID: 19443604
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
Yamaguchi T; Ueda O; Hara H; Sakai H; Kida T; Suzuki K; Adachi S; Ishii K
Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
[TBL] [Abstract][Full Text] [Related]
9. Bowel hot spots at PET-CT.
Prabhakar HB; Sahani DV; Fischman AJ; Mueller PR; Blake MA
Radiographics; 2007; 27(1):145-59. PubMed ID: 17235004
[TBL] [Abstract][Full Text] [Related]
10. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
11. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
12. Whole-body 18F-FDG PET/CT in the presence of truncation artifacts.
Beyer T; Bockisch A; Kühl H; Martinez MJ
J Nucl Med; 2006 Jan; 47(1):91-9. PubMed ID: 16391192
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
15. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation.
Wykrzykowska J; Lehman S; Williams G; Parker JA; Palmer MR; Varkey S; Kolodny G; Laham R
J Nucl Med; 2009 Apr; 50(4):563-8. PubMed ID: 19289431
[TBL] [Abstract][Full Text] [Related]
16. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.
Yeung HW; Grewal RK; Gonen M; Schöder H; Larson SM
J Nucl Med; 2003 Nov; 44(11):1789-96. PubMed ID: 14602861
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
19. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
[TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
